Arvinas (ARVN) Earnings Call Presentation

June 2, 2025 NASDAQ ARVN LISTED © 2025 Arvinas. All rights reserved. PHASE 3 VERITAC-2 TRIAL RESULTS 1 Safe harbor and forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding vepdegestrant's potential to be a best-in-class treatment in estrogen receptor ("ER")-1 ("ESR1") mutant ER positive ("ER+"), human epidermal growth factor r ...